GILEAD SCIENCES INC

📅 Upcoming

🕒 Recent(90d)

News

• STAT+: California Supreme Court sides with Gilead in ‘duty’ to innovate case
  The California Supreme Court sided with Gilead Sciences in a closely watched case over whether the company had a "duty" to innovate.
  stat · 8h ago
• J&J pays Sail $785M, charting course to possible in vivo CAR-T buyout
  Johnson & Johnson is cruising deeper into in vivo CAR-T waters, paying $785 million upfront to strike a deal that gives it the option to acquire Sail Biomedicines.
  fiercebiotech · 5d ago
• GSK cost-cutting plan includes global layoffs
  Follow along as BioSpace tracks job cuts and restructuring initiatives.
  biospace · 5d ago
• Atea’s hepatitis C asset matches Gilead’s Epclusa in phase 3 trial
  Atea Pharmaceuticals’ hepatitis C prospect has matched Gilead’s Epclusa in a phase 3 trial, keeping the biotech barreling toward a second readout for its shorter, simpler treatment regimen.
  fiercebiotech · 6d ago
• Legend Biotech CEO abruptly steps down without permanent replacement
  In a sudden leadership shift, Legend Biotech announced that its CEO, Ying Huang, Ph.D., resigned on Friday, with no permanent replacement yet named.
  fiercebiotech · 7d ago
• Study of Yescarta patients reveals genetic red flags for CAR-T therapy side effects
  A new analysis of patients who took part in clinical trials for Kite Pharma’s CAR-T cell therapy Yescarta has revealed genetic signatures of toxicity risk, potentially providing a path forward for…
  fiercebiotech · 10d ago
• Merck stages expanded access to monthly HIV PrEP pill ahead of approval
  Following in the footsteps of Gilead, Merck has signed voluntary licensing agreements to enable access to its investigational HIV PrEP pill alimatravir ahead of any regulatory submissions.
  fiercebiotech · 10d ago
• Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add on
  Roche has 19 investigational medicines that could launch by 2030—and even if not all of them make it to market, the company is “well set-up for growth into the next decade,” CEO Thomas Schinecker s…
  biospace · 11d ago
• Biopharma layoffs must double in H2 for 2026 to match 2025 cuts
  With fewer biopharmas making or planning workforce reductions so far year over year, layoff round size and M&A impact on headcounts will likely shape the number of employees who are ultimately on t…
  biospace · 11d ago
• Repligen strikes $1.5B BioLife buyout to bag cell therapy product pharmas rely on
  Top-selling cell therapies from BMS, J&J and Gilead depend on a BioLife product, positioning Repligen to use the takeover to increase its exposure to the modality.
  biospace · 12d ago